Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 1:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: FOSAPREPITANT (Emend) Clear all
Completed Phase 2 Interventional Results available

HBPL Study of the Impact of the NK1 Antagonist Aprepitant

NCT01176591
View directory record Official record
Conditions
Cocaine Dependence, Alcohol Dependence
Interventions
Placebo session 1, Aprepitant session 2, Placebo session 1, Placebo session 2
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Results available

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

NCT00954941
View directory record Official record
Conditions
Hematologic Diseases, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
Interventions
Ondansetron, Aprepitant
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy

NCT03435003
View directory record Official record
Conditions
Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy
Interventions
Aprepitant 80 mg Oral Capsule, scopolamine transdermal, Total intravenous anesthesia, Dexamethasone, Ondansetron, Reglan, Compazine, Sugammadex, Propofol, dexmedetomidine, Fentanyl, Sevoflurane, Desflurane
Drug · Procedure
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

NCT02939287
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1, Olanzapine10 mg orally daily on Days -1,0,+1 and +2, Aprepitant plus Olanzapine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Results available

Treatment for Cannabis Withdrawal and Dependence

NCT01611948
View directory record Official record
Conditions
Cannabis Dependence
Interventions
Aprepitant, Placebo, Manual-guided behavioral counseling
Drug · Behavioral
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2017 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Not applicable Interventional Results available

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

NCT02130687
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypertension
Interventions
Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT)
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery

NCT00659945
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Aprepitant plus Ondansetron, Ondansetron plus placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Results available

Multi-day Doses in Prevention of Nausea and Emesis

NCT00600353
View directory record Official record
Conditions
Myeloma, Plasma-Cell, Lymphoma, Malignant
Interventions
Palonosetron, Aprepitant, Dexamethasone
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Results available

Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial

NCT01149369
View directory record Official record
Conditions
Gastroparesis
Interventions
Aprepitant, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
San Francisco, California • Stanford, California • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 22, 2026, 1:07 PM EDT
Withdrawn Not applicable Interventional

Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting

NCT00699894
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
aprepitant 40 mg, ondansetron 4 mg
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 25 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2013 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

NCT00381862
View directory record Official record
Conditions
Colorectal Cancer, Nausea and Vomiting
Interventions
aprepitant, dexamethasone, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin, palonosetron hydrochloride, quality-of-life assessment
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Savannah, Georgia • Hilo, Hawaii • Harvey, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 1 Interventional Results available

A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)

NCT00819039
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Aprepitant, Ondansetron
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Months to 17 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Not applicable Interventional Results available

Aprepitant for Post-operative Nausea

NCT01020903
View directory record Official record
Conditions
Postoperative Nausea
Interventions
Aprepitant, Placebo
Procedure · Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Not applicable Interventional Results available

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients

NCT00651755
View directory record Official record
Conditions
Lymphoma
Interventions
Aprepitant, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab, Ondansetron
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 22, 2026, 1:07 PM EDT
Withdrawn Not applicable Interventional

Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer

NCT01017809
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Aprepitant
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Early Phase 1 Interventional

Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation

NCT00314743
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Ondansetron, Dexamethasone, Aprepitant
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting

NCT01474915
View directory record Official record
Conditions
Postoperative Nausea and Vomiting (PONV), Nausea
Interventions
Aprepitant, Ondansetron, Promethazine, Dexamethasone
Drug
Lead sponsor
Sergio Bergese
Other
Eligibility
18 Years to 85 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Results available

Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence

NCT02210195
View directory record Official record
Conditions
Cannabis Dependence, Alcohol Dependence, Cannabis Use Disorder, Alcohol Use Disorder
Interventions
aprepitant, Placebo, Manual-guided behavioral counseling
Drug · Behavioral
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Sep 22, 2026, 1:07 PM EDT
Not listed Not applicable Interventional

Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries

NCT00835965
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Dexamethasone, Aprepitant, Placebo Dexamethasone
Drug
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2009 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

NCT00717054
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Aprepitant, Scopolamine
Drug
Lead sponsor
Drexel University
Other
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 1 Interventional

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals

NCT00428519
View directory record Official record
Conditions
HIV Infections
Interventions
Placebo, Aprepitant
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying

NCT02989467
View directory record Official record
Conditions
Healthy
Interventions
Aprepitant, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 22, 2026, 1:07 PM EDT
Terminated Phase 4 Interventional Results available

Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy

NCT00888329
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Aprepitant, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Sep 22, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Results available

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

NCT01450826
View directory record Official record
Conditions
Nausea, Vomiting, Glioma
Interventions
aprepitant, ondansetron
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 22, 2026, 1:07 PM EDT